CNBD1

Across TCGA pan-cancer cohorts, CNBD1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated CNBD1 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CNBD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CNBD1 expression acts as an unfavorable survival marker.

DLBC, MESO, and STAD are the cancer types where CNBD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
STAD	OS	Median	II,III,IV	0.275	0.714	.007	15	view →
CESC	OS	Median	All	0.110	0.592	.002	12	view →
OV	DFS	Median	II,III,IV	0.219	0.542	.010	12	view →
LIHC	DFS	Median	All	0.068	0.544	<.001	12	view →
LUAD	OS	Median	II,III,IV	0.276	0.565	.013	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ESCA	DFS	Median	II,III,IV	0.149	0.522	.047	3	view →
LUSC	DFS	Median	III,IV	0.163	0.640	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

CNBD1–DLBC (DFS)

Open the DLBC breakdown →